REGISTERED COMPANY NUMBER: 08031174 REGISTERED CHARITY NUMBER: 1147658 FUNGAL INFECTION TRUST REPORT AND ACCOUNrs 30 APRIL 2022
YUNGAL INFECTION TRUST INDEX Page Reference and administrative details Trustees. Report JndepeDd¢nt examiner's rtport Statement of fanCIal activities 10 Balance Sheet 11-15 Notes to the accounts 16-17 ApndiX Scientific publications and presentations
FUTr4GAL INFECTION TRUST REFERENCE AND ADMINIST114TIVE DETAILS Trnslees Professor P J Folkman Mr P G Oxnam Mr J C Morgan Dr C Patthhurst Pmfessor J Cooke Professor R Hay Hon Secretary Mr J C Morgan Bankers Royal Bank of Scotland 56 Chestergate Maccle5field Chethire SKII 6BA Independent Eminer Roslyn Beattie Company Solutions Limited 2 Festival Square Little Germany Bradford BDI 5BD Registered Addres5 P.0. Box 481 Macclesfield Cheshire SKIO 9AR Charity Registration: 1147658 Company Regislration= 08031174
FUNGAL tNFEcfIoN TRUST TRUSTEES, REPORT The of Trusleffj who are also dJTectors of the Chariry forthe purposes of the Companie5 Act 2006. pr¢s¢nt their report and fitwjcial stat¢ments of Fw)gal Infection Tn]st for the J'egr ¢nded 30 April 2022. The financial statements have been pwared in accordance th the accountino p)licies as S on page I l and compl) with the ch2rity's trust deed. the Conwanies Act 2006 and the StstemeDt of RecoTEJAn¢ndcd Pradi¢¢ - AwFunting alld Reporting by ChaEitie% 2011. STRucfuRL GOVERNANCE AND mANAGEmEr The Fungal tnfeclion Trusl ("The Charirf or The Trust orffF} is a compony liLnited by guardntee and govemed by its M¢Tnorandum and Articl¢s of Association. DIREcfoRS AND TRUSTEES The directors of the Charitable company are its Tee5 for the Put ofchatity law and throughout this report are collettively referred to as the Tnjsttts. Tbe Trustees serving durillg the year were follow Mr PG Oxnam Chairman MrJ C Morg2U Secrtiar) Professor J c{ke (rLsigned 5 October 2022) Professor P J Folkman Profe550r R Hay Dr C L Pallkburst New trustees are intetvtewed and appoiTrted by the exi5ttJJg InCeS. Before tsking up their Fmisitions. rtew trllstecs are sent on &xternally Iraining courses where appropriate. Risk Management The Ttustees have examined tbe major strategic. busTness and opentional Tisks which the charity faces and conf systems have been established to erRble rwlar reports to be produced so that the necessary steps can be taken to lessen these risks. Organisational Structure GovernaDce The Trust is manaoed by the Tnjstees. The Trnst has no paid or volunfEry employees. Accounts are prepared by the Secr¢tary a regular b&si5 and presented to the Trusiees at their meetings. The fllwjcial status of the Trust 1$ reviewed by a Tnee sulKotnrnittee prior to each Tn]stees' Inting and its r¢wnllnendations presented to the Tneeting. A minimum of three TnteeS meetings are held each year. Responsibilvties of Trustees Law applicableio charities in Elld & Wales requires the Ttusttts toprepar¢ fin3ncial statements foreach fmancial year which give a twe and fair view of the iD¢ominu resourcL% atsl applI110n of the reSoue5 of the charity during the year attd ofits slate of affairs at the end of th¢ year. In preparing financial ststements giving atrue amd fair vi¢w. the trust¢es recognise they should follow best pctIce and.. select suitable acc¢)unting policies and then applv them consistently" ]nake judgements and estiDMtes that are reasonable and prudenL state wthether applicabl¢ uting stsDdatd8 and sNements of recommended prdctice haye been followed.
prepare the financial sÉatemeDts on the goiDg wn¢ern basis ut]less it is inappropriate lo presume that the charity will continue in oE*ration. The Trustees are responsil)le for keeping proper accoutthg records which disclose with re&sonable accurncy the financialposition ofthe ¢harity and whTrch enablethem to wertain its fvjancial position and to ensure thatthe financial statemcnts conwly with the Companies Act 2006 and th¢ Statemellt of Recommended Practice - Accounting and
FUNGAL INFEcfioN TRUST TRUSTEES, REPORT Reporting by Chariti¢s 2005 and th¢ TTUSt tk¢d Th¢y at¢ also SponSIble for saf¢guarding the &ssets of the clwity and hence for taking reasonable s*ps for the prevention and detection of fraud and other irregulartties. 0ECTIvEs AND AcrtvrriES To promotr rcsrJrch in all aspects of ¥nycology, Tnvcotic dise&se4 fungal toxicology and microbial disease (of all living things) and to publish the useful results thereof. To advance education particularly among physicians and scientists about mycology. mycotic diseases. figaI loxicology and microbial diseases in geneTa]. 3. To generally support basAc research into ng1 and fungal disease. train scientists in mycology and related disciplines. To provide infornmtion to lents suffering from fungal disease& in porticular &swgillosis. 5. To rais¢ awaren of figaI pathogens arld fill1 diseases amongst the general public in the UK and internationally. Review of Aetiyities The FIT website (i%"ii ii.fun"alinfLCtii)Iitrust.i)r¥} averdged 4A0 (rdnge 528 .- 7&1) uTJique visitors per month in late 2021 and 2022. The ¥nost popular pages are Ivhai we do, Research Grants and Fungal Disease Awareness Week. Online education in fungal mÉemscopv and histology {ii"ii"ii.microfunoj.net) The FIT continues to support the world""s first onlin¢ Micros¢opy and Ilistology course (Microfungi). To date this course bag hosted 2200 disttiict users from 132 countries (an increase froln 1849 the previous year). The ke!, participants have beerA from the United Kingdoll4 Mexico, BraziL USN Indi4 Ni. eri4 Argentin4 ColombiA Spain. nd Ghana. CuTrently this course is available in Englis]L SpanisK French. Porti]giie5e and thinese. So far 470 pass or distinction certificale5 hav¢ been awarded. All those registered on the course can re-enter the cour5¢ to refresh their knowledge at aiiy poinL Thts lleS MicrofigI an invaluable lifr-IoDg It)Ing tool for all healthcare practitioners. Typically 5- 15 users, login ¢a¢h day. The Aspergillus Website @ iiii"i¥.asper"illu5.oN.uk The Aspergillus Website has been in operation since 1998. so this is its24 year of operati¢)n. The Agpergillus Website remaims the world's most COTnprehensive reS0Ce for the pathogenic and allergenic firngi Aspergillus and th¢ di5¢as¢5 thatthey cause. It is completely free to all users. It has been supported by unrestricted educational wts from various corwrate donor& notably Pfizer, Dynamiker aTKI Gilea(L The Aspergillus Website was moved from the obsolete oper2tints system it was bed on in late September 2020, $0 this is the end of its second year on its new plarform In WonlPress- a move made possi1¢ by the continuing success and expansion of that sysiem worldwide and its Tmproved ability to n]n a website the size of the ASperlIuS Website. It ha8 consistently well on WordPress over the two year& A drawback of moving the underlying collte]rt nwetnent system (CMS) of any websit¢ is that almost all of the links are change(L which taS thal all searches in anv seah engine become out of date oyernighi. As Tnanv visitors to most websites arrive as a result of Googlc and Bing s¢archcs (and others) this means that overall user number sharply drops. In tb¢ of th¢ Aspewllus Website it dropd from an average of 1000 users per day to 400 users per day. Steps were taken to ensure the new website links would be tsken up by s&vch ¢ngine5 a5 quickly 18 possible and the number of users ros¢ to 500 day by end of 2020. The illcre colltiDued up until summer 2021but h&s dropped in early 2022. The Aspergillus Website is Still read Very widely across the Worl with (in order of usage, highest to lowest) China, USA. UK. India Ond Austrnlia making up 65/• of users. Chin4 USA UK Indi4 Australii Gerniany Canada, Philippines, France and Russia are the most frequent users. The proTnin¢n¢e of two non-Ellglish speaking countrie5 in the top 6 {and 4 more in the top 10) may reflect our decision to add in automati¢ language ttanslation of the entire website when the website w&s moved to WordPrE The Aspergillus Wcbsitepn>vides freeeasy xcessto >74.0 pages. over 15,400 scientific articles (including a unique collection of 836 historical articlcs) and over 172(M> conlerence absuacts from 1974 onwards. The Aspergillus Website bas b¢¢n rn95tly viewed on desktop PC (660/17) rather than mobile {33/0) in 2022. possibly reflecting the professional nature of its user5 and most of the rESt of the world use mobile phones to browse websites.
FUNGAL INFEcfioN TRUST TRUSTEES? REPORT Fig 1. 90 days F¢b-April 2022 The comprehensive lisl of drng5 and drug iterneti0s with anllfijngals is continually updated. The drug interaction database I iiTri"Il'.L%PLriTillus.onF aniifunJl4ru<'_interactions ) (rncludiTtg the antifungal dnig intera¢tiOD app for android phone5} is popular alld well used. Links from other websites to this specific part of the website have been added. L£adin InternatiOT Fun(val Education LIFE June 2021- Ma 2022 The LtFE Worldwide website recorded 103k users during this perio(i wÉtih 119k individual visits. This figure is doNvn on 2020121 as we be(Tan to rnIte content away from this platfom) on io the new iii%K4.lunJo leducation.i)pTr site. We estitnate that this traffic will transfer across to th¢ new sife during 2022123 and we will see a steady growth in users &$ we rnaA(et these new resources. We launched the nem. plarfonn iiiiii".fun<JalLduCaTlnn.nr in 2022. Work is ongoing to add and develop content for the new site. It was widely promoTrd ai the intemationa] ECCMID rneetintt in Lisbon. 200TZQ3 will focus on Other marketing the platforn] and targeting splfi¢ global audiences. The Spanish pages continue to p)pular and well-used indicating a need for to prllt the w¢bsite in multiple languages.
FUNGAL INFEcfioN TRUST TRUSTEES, REPORT Page Page¥ie Sessions byco Ilungahfssease5JfwgohJJhure IS7 lesplfungakyltu 11115 7.470 Ifungapdiseases 4.ITJ /fwgal•iseasesinuK1s 3.881 /funoal.diseaseslhistopathrA 3.465 iespifungal.diseasesnine&cruris 3.411 lrnedientrelartie...l1uC0rJaZQ1e-tOI0ts 3.179 /fungal4iseastsifurqb 1541 Jun i, 2Ql - May31. 2022 20 Overthe last 90 days we have recordedover7W users onthe new s¥te. with arow)d45Q/o ofthes¢ a¢£¢ssingthe Spanish version of the site. Our YouTube channel continues to be an irnpacffiil part of the LIFE Worldde edllcational offering. As well as adding three new videos on dtugldrug intera¢tions we also had the exceptional MlestOne of one of our Trideos passing 100.000 views. Over the year ow ¢hann¢l IK5 received 105,000 Waiche5, equating to almost 4.000 hours of viewing time. Our top 5 countries by audience are India (35°hA United States (130/0), Banglad¢sh (41/Jo), Pakistan (3 /oland Philippines (20/0). LIFE Worldwide continues to make a 5ubstsntial impact OD Twitt. During 202 If22 our Tweets received over 192.000 impre&sions. and we saw a steady growth of followeTS (20.50/0 groThxh over the year). The Tweet with the biggest impaci was promottng the Center For Disease Control's Fun0 l Disease Awareness Week We ate usingthis data io build a marketing calendar for 2022f23 to utilise the various global awareness days and to use these to rdise our profik. A to]nponellt ofthe LIFE efforthas beentoboost awar&)ess of fimgal infections generally. b). quantifving the problem better. This has involved estilnating the burden of serious fitraI disease in over IIM) counirie& to highlight the seriousnes5 of a range of primary and secondary fungal dise. Additions since last year's report are underlined. PublTshed in jOUTnals {x81).' Al.eri4 Ar.tsentin4 A%tri< Azerbaijan. Ban<yladesh. BelgiunL Brdzil. Bllrkina Faso. carner00 Canad4 Chile, Chin4 Colornbi4 Congo (Republic ofj, Cotr d'Ivoire, Czech Republic. Dem(watic R ublic of Con DRC DenmarK Domini& Republic, Ecuador. EW Erit Ethiopi4 France, Germ2ny, Ghana, (irerfe. Guatemali Honduras Hungarv. ITJdi4 Indonesi Ira Irelall¢ IsraeL Italy, Jamaic4 Jordan, Ka7akhstatJ, Keny4 KuwaiL KyTgyzslan. Malawi. Malaysi4 Mexico. Morocco MOZabiqUe, Namibi4 Nepal. Netherlands. Nigeri4 Nonway, 0rn2n, P8k]st Pen4 Philippines, Pornjgal, Qatsr. iiomaniL Russii S¢negal, S¢rbi4 Sierra Leone South AfrAc4 Spain: Sri LanW Sweden. Taiw TajTri%t Tan2ani4 Thailand: To Tr2nidad and Tobago. Turkey, UgandL UK Ukrnin4 Uruguav. Uzbekistan, Vietnam and Zimbabwe. Published bdell papers are available at https=l/iwwv.gaffi.nrR/medi¢i/aiddL'InIL-papLrs1. Pr¢sented in ab5ttacVposter forni at conferences but not yet published (x13): Australi4 Belatus, Ben1 Iraq. Japan. Madagascar, Mongoli4 New Zealan<L Parnguay, Saudi Arabi4 Singapore. Venezu¢l4 Zarnbia (detail is available th¢ LIFE website iti tILe news section http=//1%¥.Il(e-V0rIdiy1de.0rg1med&a-LentrelThLlvsj. Top media Tweet .. s 2¢DCgov FurvJal Disease Awareness Week. Th[(WUl Ihe week well hvJhSghting relevant resources for you lo aotess to le8m more abwt the global tywact offungal diseases. hinklungus #meded Yu#galimfÈctton avreneSS duCation researCh *trycolDyy DlC.tt'Jrtlertom,'qV3ZBpxh7D SEVtEMBER 2U-24. zl1
FUNGAL INFEcfioN TRUST TRUSTEESY REPORT Burden of disease estimates r4osiL The FIT also supported several tmwrtaDt Teseah publications and review5 (see Apnd1X). There were 15 peer- rewewed publications calendat year 2021 a dirttt consequence of FIT grants and lIabotiOS. The notsble outputs include.. Two papers describing the diagnoslic perforIce of the new ]nt of care assay for Aspergillus antibody - r¢lat¢d to subile immunodeficiency and in Indonesi Country burden of disease estimale5 for 6 countries tn 2021, includiDo 2 highly popul0 countries- DRC and Indonesi A review of antifungal dNg interaction& linked to the online database: ..8Sper druiT-interaitii)n Two papers related to how pToftssional phagocytes in the blY actuall kill Aspergillw fiJng]. cFillus.upF uk.'antifungal- During the year support was given to research proj¢cts at thc Univ¢rsity of Pen]gi4 ltsly; the Medical Research Foundatio Trinidad and Tobago; the UniveTsity of tknmé, Togo. the Université de Montagnu Bangante. Cameroon. Travel and Livino Allowance Grdnfs for attendance and presentstion at scientific conf¢r¢n¢¢s iotalling £780 (2021 Nil) were rnade durtng the year as part of the Trust's policy to support scientists in the early stages of th¢iT ¢or¢¢rs in mycology. Who benefited from the Trust's Aclivities? Researthers in the study of funj (Mycolo). respiratorv medicine and infectious diseases from all over the world Medical doctors. especially tILrough th¢ Drug Interactiolls database Patients alld theirGqrers. Students of medicine. Pharn0y. biology and microbiology The public- School childre tbeir teachers and parents. How do the Trust's Activities Ben¢fit tbe Publie". Awarelless of fungal disease Te]narns low among the general public. The HT website ¢nables the public to access reliable ]nfOrntiOn quickly on this topic. auglnented by the lltore specialed web resources at LIFE-Worldwide and the Aspergillus W¢bsit¢. Th¢ r¢brnided Ftr website a]50 re-posts press and general sÈories and explanatory articles for easy access for all. Futsre p13llS In2022. an update and overhaul ofthe Microfitngi ethjcational website is plannd EffoTts to promotethe FITT¢soiirces internationally are planned at major conf¢rerK¢s in Eur(ryK, USA Asia andAfrica The Aspergillus Website continues
FUNGAL tNFECTION TRUST TRUSTEES, REPORT to provide a valyable resOUe internatio[ly. some additional contenL The FIT will resp)nd to grant requests as it has done previousl).. FINANCIAL REVIEW, The results for tbe periid ar¢ set out on page 9. There was a d¢ficit of Income over ExFthdits]re for the year of £70,?00. (2021 £36,liO). Corpornte Governance eXlditure represented 20.700/0 of total income {?021 14.500/0). DurinLV the yeor the re-design of the Fung21 Infertion Website was completed at a cost of £1200. As a result of the restrictions placed uwJTr us b¢¢ause of the COVIt19 Pdthdemic all Trustees rneetings were held using ZOO as a consequence no Tn¢¢5 Extnses or Meeting Costs were in(2llre lllves¢meDt Poly The tsStee8 do not consider th* they bave sufficient free Twrves to invest surplus fjmdq for any mediutn to long terni. Consequently, are maintAined in a bank dew)sit account Reserves Policy The chaTiry have established alleY to maintain unresthcted fiJndsTh)t committed or invested in fLxed assets i.¢. 'free reserves, & a level of betw¢¢n one and two Yea of unrestrieted expenditur¢. This provides sufficient levels of fidS to be ableto continue the current aCtIlieS of the charity and io pr(>vide sufficient time to consider 8T)d replace existing funding sources should there be a significant change in presellt fi]ndtng arrdngements. The reserves p)licy is reviewed annualty. Secretariat The Trustees wish to express their appreciation of the WOTk undertakth by Mr J Morgon in rU[mi the secretirtat and administrativ¢ tilltIOns of the TruA during the pasÉ year. Independent Examiner In accordance with the Trust Dee(L a prnp)$ to rtrappoint Company Solutions Lirnited for the forthcoming ye will be put to the general meeting. On behalf of the Trustees Phillip Oxt 5 October 2022
FUNGAL INFECTION TRUST INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF FUNGAL INFECTION TRUST I report to the trustees on my exaMItiOn of the financial statements of Fungal Infection Tn]st (th¢ charity) for the year ended 30 April 2022. Responsibilities and basis of report As the tsijstees of the charity (and also its directors for the pu)seS of company law) you are responsil)le for the preprtion of the fjnancial statements in accordallce with the requtrements of the Companies Aet 2006 (the 2006 Act). Elaying satisfied myself that the financial 5rateellts of the th&ity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examinatiory I repTrrt ID re5IKrt of my eXa]natiOn of the charity's financial statements CaTried out under seuion 145 of the Charities Act 2011 (the 2011 Act). In carryllig out my &xamination I bav¢ followed all the applicable Directions given by the Chariry Commission under section 145(5)(b) of the 2011 ACL Independent exaer,S statement I have COTnpl¢ted rny examination. I confinn thai no mauers have come to att¢Trtion in connect with the examinatioTh gtving Jne cause to believe that in any material respect: accounting records were not kept in respert of the charityas required by section 386 ofthe 2006 Act,. OT the financial statements do notatcord with those records: or the financial statements do not comply with the accounting requirements ofsection 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is nota matter considered as part of the independent exatnination: or the financial statements have not been prepared in accordance wtth the methods and principles of the Statement ofRecommended Practice for accounting and reportKng by charities applicable to charities preparing theiraccounts in accoTdance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102). I have no concerns and have come acri no other matters in connection with the examination to which attention shoul drawn in this report in order to enable a proper underathg of th¢ fiDallcial statements to be r¢ath¢ Roslvn Bea Company eFCA lutions Limited Date October 2022
FUNGAL INFECTION TRUST STATEMENT OF FII¥4ANCIAL ACTIVITIES PERIOD ENDED 30 APRIL 2022 Totsl funds Year to 30 April 2022 Total funds Y&v to 30 April 2021 Unrtsirnt Designated funds funds 21ll2 Note 21b22 INCOMING RESOURCES IDcomiDg rtsollrees from generxted funds Voluntary income." Donation5 and gants Activities for ge¢ratIng fuDd&" 20.918 20,918 17,535 Investment ineome Incoming resources from cbaritsble activitie% Dollations and grants 30 30 48 l R.435 11.435 119.503 TOTAL INCOMING RESOURCES 20.948 32,383 137,086 RESOURCES EXPENDED Costs of charÉtable aetivities Charittble a¢tiVilies 40,091 55,789 95.880 153,359 Governance costs 6,703 6.703 19.877 TOTAL RESOURCES EXPENDED 46,794 55.789 102,583 173,236 NET MOVEMENf IN FUTrIDS -25,&16 44,354 -70200 -36.150 Trdnsfers betwecn fill Totsl Funds brOt foTwatd 105.217 116215 221,432 257,582 TOTAL FUNDS CARRIED FORWARD 79J71 71,861 15 1.232 221.432 The statement of financial activities include5 all gdins and losses recognised in the perio All incoTn¢ alld CxpUith derive from colltinuiog activities. The statement of financial activities also complies with the requirements of an income and expenditure account under the Cojnpatiies Act 2006.
FUNGAL INFECTION TRUST BALLNCE SHEET AS AT 30 APRIL 2022 2022 2021 Note CURRENT ASSETS Debtors Cath at bank 26.162 229.181 163,580 171,480 CREDITORS Amountg falling due withill one year 255.343 20248 33,911 NET CURRENf ASSETS 151232 221,432 NET ASSETS 151232 221,432 ACCUMULATED FUNDS Restricted fi]nds Designated General unrestricted fi]nds io 71,861 79,371 116,215 105.217 151232 ?21,432 The ¢haritable mpany ts ¢ntttled to exemptlon from audii under Section 477 of the Companies Act 2006 for the period ended 30 April ?022. The Trustees have not required the Chitable company to obtain an audit of its financial statements for the p¢riod ended 30 April 2022 iu accordance with SerttoD 476 of the Companies Act 2006. The TrStee5 acknowledge their responsibilities for. a) ¢nsuring that the charttable company ke¢p5 accouDting reconls that cornply wxth Sections 386 and 387 of the Compani-s Act ?006 2nd b) preparing fllW)cial staEements which ve a true and rair view of the state of affairs of the ¢haritsble company ag th¢ end of financial yeaT and of its Surpl$ or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and iTrhich otherwse cornply with the rquitrments of the Cotnpanie9 Act 2006 relating to financial stoterneftt% so far as 2ppli¢able to the c])aritabl¢ company. Th¢se fancIal statements have been prepared in accoTdance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable eompamies and with the Finallcial Repjrting Standard for Smaller Entities {effective April 2008). The financial stAt¢ments w¢re approved by the Board ofTnL%t¢es onl*5 October2022 and were signed on Its behalf by: Mr J C Morgan io
FUNGAL INFECTION TRUST NOTES TO THE ACCOUNrs FOR THE YEAR ENDED 30 APRIL 2022 CHAIUTY INFORMATION Funtsal Infection Tnt is a private company limated by ouardniee incorporated in England and Wales. The registered office is P.O.B 482. Ma¢cl¢sfiel¢L Cheshire. SKIO 9AR I. ACCOUNTING POLICIES The principal accounting policies adopte¢ judgements and key sources of estimation of uncertainty in the preparation ofthe financial statements aTe &8 follows: Basis of preparation The financial sthiements have been preped in accordall witb Accounting and ReportiDg by Chariti¢s.' Statemeni of Recommended Practice applicable to ctwitie5 preparÉllg th¢ir ar¢ounts in accordance with the Financial R¢porting Standard applicable in the UK alld Republic of Ireland (FRS 102) (effective l Januarv 2015)- (Charities SORP (FRS l(r2)), the Financial Reporting Sthndard opplirable iJ) the UK and Republic of Ireland (FRS 102) and the CompaDies Act 2006. FIT meets the definition of a public b¢D¢fft ¢ntity und¢r (FRS 102). Assets and liabiliti are inikna]ly recognised at historical c(t ortransaction value ut)less othetwise stated in the relevant accounting policy note(s). b) Goillg ConceTD At the time of approviT)g the finallcial Stste[nen the trL8tees have a re&8onable expectstion that the charity has adequAte resources to continue in opemional existence for the foreseeable fiLture. Th8, the tteeS continue to adopt the going couc¢rn basis of ao¢ounting in preparing the financial statsments. The thatity rnaintains the following t)yes of fios. DeSitedfidSreprest gr2nL% donations and lewies received which allocated byth¢donor for specific pun)oses. General unrestricted fimd r¢pr¢sents Ucted inC0C which is exFDdable at the discretion of the trustees in the furtherance of the objects of the charity. Such a fund may be held ID ord¢r to finance both working capital and capital investtnellt. There are no restricted fimds in the Charity. d) Incoming Resources All in¢omints resourtts are reco]Sed once the charity ])&8 eniitlement to the resources. It is certain that all the resources will k received and th¢ Tnonetary value of iticomiDg resources can be measured with sufficient reliabilitv. ii
FUNGAL INFECTION TRUST NOTES TO THE ACCOUNTS FOR TIIE YEAR ENDED 30 APRIL 2022 e) Resowces Expended Exp¢nditur¢ is rttog]is¢d on an acc1 basis &s a liability is in¢wTed Extnditille includes any VAT which cannot be fijlly recoyered, and is retx)rted as p&t ofthe expellditure to wthich it relates: Costs of gen¢rating fimds ¢ompris¢ th¢ Costs asso¢iat¢d wtth attra¢ting volulltary in¢om¢. CIlIable ex[ture comprises those costs inewred by the elthrity in the delivery of its activities and services for its beneficiaries. Jt Includes knth costs that can be all(atrd dI[tlY to such activities and tbo CO*s of an indirect atUre necessary to support them. This exFtnditi]re iJJ¢ludes all expenditure directly relatrd to the objects of the charity. Governallce costs include those costs associated with rneeting the constitutional and statutory requirements ofthe charity and include the independent eKatnin¢r's fees and costs linked to the strategic managejneni of the clwity. fj Taxation The charity is exenipt from coiimtion t&x on its cknitable actibTrtie& DONATIONS AND GRApirs Total fuDds Year to 30 April 2022 Total funds Year to 30 April 2021 GeDer41 UDresÉrieted FuDds 2022 Designated FuDd$ 2022 Genernl donations 20.918 20,918 17,535 Genera] donaÈions include sundry amounts donaied to the charity by members of the public. No gifts in kind have beell received in either the cuThent or previous year. ACTtVlTIES FOR GENERATING FUNDS INVESTMENT INCOME General UDrotricted Dds 2022 Totsl fulld5 Year to 30 April 21)22 Total fi]nds Year to 30 April 2021 Designated Funds 2022 Bank inler¢5t 30 30 48 12
FUNGAL INFEcrtON TRUST NOTES TO THE AccouIYrs FOR THE YEAR EIYDED 30 APRIL 2022 INCOMJNG RESOURCES FROM CHARITABLE ACTIVITIES Dof4ATIONS AND GRANTS Total funds Year to 30 April 2022 Total funds Year to 30 April 2021 Gellenl UDrestri£te DesigDatsd Funds Fullds 2022 2022 Gil¢ad Pfizer ZamboJJ Mayne Pharnia Huskisson D)ryJamiker SuDdry 7,900 7.900 23.700 34,625 17,009 11,042 31,250 3,535 3.535 1,877 119,503 COSTS OF CHARrrABLE AcfMTIES Totsl futlds Year to 30 April 2022 Total funds Year to 30 April 2021 Un&1 Designated rullds funds Note 2022 2022 Donations and grants Project costs Travel grants Governance costs 40,091 42,763 13.026 82,854 13.026 118,385 34,974 6.703 6,703 19,877 46,794 55,789 102.583 173.236
FUNGAL INFECTION TRUST NOTES TO THE Accouwrs FOR THE YEAR ENDED 30 APIUL 2022 COSTS OF CHARABLE AcrIvrrtES FR0CT COSTS Totsl fuDds Yearto 30 April 2022 Total funds Year to 30 April 2021 UJw¢sti7 Designated funds funds 2022 2022 UveIty of Manchester Research Team (iO.IKK>) (10,000) 10.000 Otber activity costs 23.026 23,026 24,974 13.026 13,026 34.974 GOVERNANCE COSTS Totsl funds Year to 30 April 2022 Total fid$ Year to 30 April 2021 Generni Designatsd fuDds lunds 2022 2022 Insurance Legal and professional Trav¢1 and meetÈng costs PrintingJpostage/statioDery Accountanry fees Bank ¢harg¢s Promotion Costs FIT Website Costs 810 13 150 458 1200 162 810 13 150 458 1200 162 810 13 681 1,150 138 953 16,132 3.910 3,910 6.703 6.703 19,877 DEBTORS 2022 2021 lllvoiced 7.900 26,162 CREDITORS: Amounts fallittg d¢ witbiD ODtrytar 2022 2021 Accruals 20248 33.9RI 14
FUNGAL INFECTION TRUST NOTES TO THE AcCOUs FOR TIIE YEAR EIYDED 30 APRIL 2022 10. MOVEMENT IN DESIGNATED FUNDS Imay 2021 GJitL% 30 ApAI & Transfers 2022 ID(XTrJne Aspergillus Websit¢ 84.965 11.435 13,026 83,i74 Stella Huskisson meorIal Fuud 31.250 3 1,250 LtFE-Worldwide 42,763 {42,763) 116215 11.435 55,789 71.861 11. RECONCILIATiof¥ OF MOVEMENTS IN GENERAL FUM)S 2022 2021 Deficii (20215UTplus) of income over expeladiture for the y&qr Funds at the beginning of the year -25,846 105,217 25.771 79.446 Funds to fmvard 79J71 105.217 12. ANALYSIS OF ASSETS AND LIABILKTJES BETWEEN FUNDS c¢Tl UDrestri¢ted funds Total ftsnds 2022 DIgnated funds Current assets C&sh at bank and in hand D¢btor5 Current Itabilittes 92,917 70,663 7.900 -6,702 163,580 7.900 -20,248 -13.546 79,371 71.861 J5
FUNGAL INFEcfIoN TRUST NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2022 APPENDIX Publications supported by the Fungal Infection Trust in 2021 l. Stucky Hunter E. Wilopo B, Richardson MD, Kosmidis C. Denning DW. Effect of patient immun(Kleficiencies on the diagnostic perforn)ance of serological assays to detect A5pergillus-specific antib(Mli£s in chronic pulmonary aspergillosis. Resp Med 2021-178=106290. 2. Gago S. Overton NLD. Bowyer P. CIUSPR-C&s9-Mediated Gene Silencing in Cultured Human Epitheli& Meth(th Mol Biol 2021.2260:3747. 3. KotTi D, Ira V. Bonouman IV, Tour¢ AO, Kouadjo F, M'boh N'GRE, Sylla K, Dossom. Dennino DW. Estimatss of Serious Fungal Infection burden in Cote d'lvoire and Country Health Profile. J Mycol Med 2021;31:101086. 4. Roz21iyani A. Setianingrum F. A7ahra S, Abdullah A Fatril AQ Rosianawati El. Burhan E. Handayani D, Arifin AIL Zaini J, Tugiran M. Adawiyah IL Syam 11 Wiknwo H. WahwningsThi 11 Kosmidis C, Denning DW. PerfoTmance of LDBio Aspergillus WB and ICT AntiEKty Detection in Chronic Pulmonary Aspergillosis. J Fungi (Basel) 2021-7(4)=311. 5. Niazi-Ali S. Atherton GT. Walczak Denning DW. Drug-drug interaction database for safe prescribing of systemic antifimgal agents. Ther Adv Jnf¢¢tious Dis 2021.8:1- 6. Kuate MPN, Nyasa IL Maodengue C. TendongforN. Bongomill F, Denning DW. Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detrtion enzyme in]muno&wy: A pilot swdy in Camerwn. J Microbiol Methods 2021=185..106226. 7. Pfavayi LT, Denning DW, Baker S. STr1 landa EN: Mutapi F. Deterniining the burden of fungal infections in Zimbabwe. Sci Rep 2021;11:13240. 8. Denning DW. Diagnosing pulmonary aspergillosis is much &Ier than it used to be: A new diagnosti¢ landscape. Int J Lung Dis TB 2021.25:525-536. 9. SueiriFOlivares h£ Scott J. Gago S. Petrovic D. Kouroussis E. Zivanovic J. Yu Y, Strolkl M, Cunha C. Thomson D, Fortun¢-Granl IL Thus¢k S, Boi¥y¢r P. Beilhack A, Carvalho A, Bignell E, Filitx)vic MIl Amich J. Fungal and host protein persulfidation are functionally correlated and En(MJulate both virulence and antifungal response. PLOS Biol 2021"19(6):e3001247. 10. Ben-Gha72i N. Gago S. Thomson D. Seidel C. Moreno-velsaquez S. Denning DW, Read N, Bosvyer P. A hiJ(F _resolution automated quantitative confocal microscopy approach to ¢haracterise A.fumigalus fafr within airway phagolysosomes. J fungi 2021-7..454. I I. LAkoh S. Orefuwa R Kamara MN. Jilm DF. Kamara JB. Kpaka S. Denning DW. The burden of serious fungal infections in Sierra Lwne: a national estimate. Ther Adv Infectious Dis 2021.8=1-12. 12. Wahyuningsih IL Adawiyah IL Sjam IL Prihartono J, At Wulandari E, Rozaliyani Ronny 11 Imrdn D, Tugirdll M. Siagian FE. Denning DW. Serious fungal disease incidence and Pvalence in Indooesia. My¢05¢5 2021:64:1203-12. 16
FUNGAL INFECTION TRUST NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 APIUL 2022 13. Kamwiziku GK Makangara JC. Orefuwa E. Denning DW. Serious fi]ngal diseases in Democratic Republic of Congo - incidence and prevalence estimates. Mvcoses 2021.64:115949. 14. Rowley J, Namvar S, Gago S, tAbram B. Bowyer P. Richardson MD. Herrick SE. Differential Proinflammatory Responses toAspergilltLsfvnigttsw by Airway Epithelial Cells In Vilro A Protease Dependent. J Fungi (Basel) 2021;7(6):468. 15. Dorkenoo AM. Adjetsy-Toglozombio AK OCaTY BK Sossou E. Lack F, Denning DW. Estinted Burden Of Serious Funool Infections In Tooo. Mycoses 2021.64:153541. 17